ClinicalTrials.gg
CompletedNCT01691677CLEARUpdated Mar 29, 2017

beCLomethasone Efficacy in Acute Rhinosinusitis - CLEAR Study

A Phase 3 interventional study of beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days and placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days in Acute Rhinosinusitis, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 3 sites in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-03-29.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Rhinosinusitis with a site in Italy — 5 open to participants now, 9 under way, 4 of them phase 3. Rhinosinusitis · Italy.

Enrollment
7th of 10
166 · median 199
Started
2013
the only one that year
Phase 3
5 of 14
1 open now
Registered
1st of 14
by date
Lead sponsor
1 of 14
Chiesi Farmaceutici S.p.A.

Among the 14 studies in Rhinosinusitis with a site in Italy, this one is the 7th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2013, is one of 5 in phase 3, and was the 1st registered.

Rhinosinusitis

251 studies on the registry are indexed under Rhinosinusitis; 69 are open to participants now.

Browse Rhinosinusitis studies →

Open to participants now

5 of the 14 studies in Rhinosinusitis with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 33 Rhinosinusitis studies recruiting now, 14 (42%) set no upper age limit and 13 (39%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Rhinosinusitis with a site in Italy, or all of them as a file.
02

Study summary

Intranasal corticosteroids are beneficial in the treatment of acute rhinosinusitis. As adjunctive therapy to oral antibiotic treatment, mometasone furoate at doses of 200 μg or 400 μg twice daily, was well tolerated and significantly more effective in reducing the symptoms of rhinosinusitis than antibiotic therapy alone. Furthermore,the addition of fluticasone propionate to xylometazoline and antimicrobial therapy with cefuroxime improved clinical success rates and accelerated recovery of patients with a history of chronic rhinitis or recurrent sinusitis who present for treatment of acute rhinosinusitis.

The present study was planned to assess the effects of nebulised beclomethasone dipropionate given as add-on therapy to standard care (oral antibiotics) in the treatment of acute symptomatic rhinosinusitis. Antibiotic therapy will be at the physicians' discretion.

03

Conditions studied

  • Acute Rhinosinusitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject's written obtained prior to any study-related procedures
  2. Male and female out-patients aged between 18 and 65 years (inclusive).
  3. History of previously diagnosed recurrent or chronic sinusitis that necessitate antibiotic therapy as judged by the investigator.
  4. Clinical diagnosis of acute rhinosinusitis defined, according to the European Position Paper on Rhinosinusitis and Nasal Polyps 2007 (20), as the sudden onset of two or more relevant symptoms for \<12 weeks, at least one of which is:

    • Nasal blockage/obstruction/congestion, OR
    • Nasal discharge (anterior/posterior nasal drip);

    AND the second one is:

    • Facial pain/pressure or/and reduction/loss of sense of smell.
  5. A cooperative attitude and ability to be trained to use correctly the nebuliser with intranasal nose piece.

Exclusion criteria

Exclusion Criteria:

  1. Previous sinus surgery;
  2. Sinus lavage within the past 7 days;
  3. Nasal polyposis or important nasal septum deviation;
  4. Antibiotic use (by any route) in the past 30 days;
  5. Recurrent moderate epistaxis;
  6. Chronic bacterial sinusitis with evidence of failure of antimicrobial therapy;
  7. Intranasal or systemic use of within the past 30 days;
  8. Chronic use of corticosteroids or agents;
  9. Immunocompromised states;
  10. Diagnosis of bronchial asthma or (COPD);
  11. History of cardiac (i.e. congestive heart failure or severe hypertension), renal (i.e. kidney failure), psychiatric (i.e. depression or mood disorders), hepatic (i.e. cholestatic jaundice or hepatic dysfunction), endocrine (i.e. hyperthyroidism or adrenal suppression) or pulmonary disease, or laboratory testing abnormalities, whose sequelae and/or treatments can interfere with the results or treatments of the present study;
  12. History of psychiatric diseases likely to require treatment with antidepressant drugs during the study period or treatment with antidepressant drugs in the past 2 weeks;
  13. Diagnosis of glaucoma or prostatic hypertrophy;
  14. History of alcohol or drug abuse;
  15. Allergy, sensitivity or intolerance to study drugs and/or study drugs formulations ingredients (e.g. corticosteroids);
  16. Pregnant or lactating women or all women physiologically capable of becoming pregnant UNLESS they meet the following definition of : 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/mL or are using one or more of the following acceptable methods of . surgical sterilization (e.g. bilateral tubal ligation, hysterectomy) hormonal contraception (implantable, patch, oral) double-barrier methods (any double combination of: IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap). A pregnancy test (urine) will be performed at screening in women of .
  17. Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study.
  18. Participation in another trial in the past 12 weeks or patients previously enrolled in this study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
166 participants (actual)

Study arms

  • Experimental
    beclomethasone dipropionate

    beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days

    Drug: beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days

  • Placebo comparator
    placebo

    placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days

    Drug: placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days

Interventions

  • Drugbeclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days

    Drug page: Beclomethasone

  • Drugplacebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days
06

What researchers measure

Primary outcomes

  1. proportion of patients who will experience clinical success

    Time frame: 28 days

Secondary outcomes

  1. overall sinus symptoms

    Time frame: 7,14,21,28 days

  2. changes of each symptom

    Time frame: 7, 14, 21, 28 days

  3. level of work performance based on patient perception (recorded on a VAS scale of the diary card) and on missed working time

    Time frame: 7, 14 days

  4. absence of relapses

    Time frame: 7, 14, 21, 28 days

  5. nasal mucociliary transport time

    Time frame: 7, 14 days

  6. nasal air flow resistance

    Time frame: 7, 14 days

  7. Adverse events and adverse drug reactions

    Time frame: 0, 7, 14, 21, 28 days

  8. vital signs

    Time frame: 0, 7, 14, 21, 28 days

07

Study locations

3 sites
  • Ospedale Cisanello
    Pisa, Italy
  • Policlinico Univesitario Gemelli
    Roma, Italy
  • Policlinico Santa Maria alle Scotte
    Siena, Italy
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2012
First posted
Sep 25, 2012
Start
Jan 2013
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Last update
Mar 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01691677
Responsible party
Sponsor
First posted
Sep 25, 2012
Start date
Jan 2013
Primary completion
Jan 2014
Completion
Jan 2014
Last update
Mar 29, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beclomethasone

Start the discussion